Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy

• Published in: Frontiers in oncology 2021-04, Vol.10, p.615472
• Main Authors: Su, Jing, Song, Qianqian, Qasem, Shadi, O'Neill, Stacey, Lee, Jingyun, Furdui, Cristina M, Pasche, Boris, Metheny-Barlow, Linda, Masters, Adrianna H, Lo, Hui-Wen, Xing, Fei, Watabe, Kounosuke, Miller, Lance D, Tatter, Stephen B, Laxton, Adrian W, Whitlow, Christopher T, Chan, Michael D, Soike, Michael H, Ruiz, Jimmy
• Format: Article
• Language: English
• Subjects: bioinformatics analysis; brain metastases; craniotomy; distant brain failure; Oncology; proteomics; RNA-Seq - RNA sequencing
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.615472

The incidence of brain metastasis continues to increase as therapeutic strategies have improved for a number of solid tumors. The presence of brain metastasis is associated with worse prognosis but it is unclear if distinctive biomarkers can separate patients at risk for CNS related death. We executed a single institution retrospective collection of brain metastasis from patients who were diagnosed with lung, breast, and other primary tumors. The brain metastatic samples were sent for RNA sequencing, proteomic and metabolomic analysis of brain metastasis. The primary outcome was distant brain failure after definitive therapies that included craniotomy resection and radiation to surgical bed. Novel prognostic subtypes were discovered using transcriptomic data and sparse non-negative matrix factorization. We discovered two molecular subtypes showing statistically significant differential prognosis irrespective of tumor subtype. The median survival time of the good and the poor prognostic subtypes were 7.89 and 42.27 months, respectively. Further integrated characterization and analysis of these two distinctive prognostic subtypes using transcriptomic, proteomic, and metabolomic molecular profiles of patients identified key pathways and metabolites. The analysis suggested that immune microenvironment landscape as well as proliferation and migration signaling pathways may be responsible to the observed survival difference. A multi-omics approach to characterization of brain metastasis provides an opportunity to identify clinically impactful biomarkers and associated prognostic subtypes and generate provocative integrative understanding of disease.